Landiolol: A Review in Tachyarrhythmias

Drugs
Yahiya Y Syed

Abstract

Intravenous landiolol [Rapibloc® (EU)], an ultra short-acting highly cardioselective β1-blocker, is approved in the EU for the rapid short-term control of tachyarrhythmias in the perioperative and intensive care settings. It has long been used in Japan to treat perioperative tachyarrhythmias. The efficacy of landiolol has been demonstrated in a large number of randomized controlled clinical trials. Landiolol significantly reduced heart rate in patients with postoperative or intraoperative supraventricular tachycardia relative to placebo and in those with atrial fibrillation/flutter and left ventricular dysfunction relative to digoxin. It was more effective than diltiazem in converting postoperative atrial fibrillation (POAF) to normal sinus rhythm. Perioperative prophylactic administration of landiolol significantly reduced the incidence of POAF during the first week after cardiac and other surgeries, compared with diltiazem, placebo or no landiolol treatment. Landiolol also attenuated adverse haemodynamic and other responses to invasive procedures such as percutaneous coronary intervention, tracheal intubation, extubation and electroconvulsive therapy. Landiolol was generally well tolerated, with a relatively low risk of hypot...Continue Reading

References

Nov 2, 2005·Journal of Anesthesia·Toru GoyagiToshiaki Nishikawa
Dec 6, 2005·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Shigeru SaitoNaoya Yuki
Nov 18, 2008·Journal of Anesthesia·Kazutoshi IkeshitaAkira Asada
Jan 29, 2011·The Journal of Thoracic and Cardiovascular Surgery·Akira SezaiAtsushi Hirayama
Jun 5, 2012·Heart and Vessels·Hiroyuki NishiYoshiki Sawa
Aug 4, 2012·The Journal of Thoracic and Cardiovascular Surgery·Akira SezaiAtsushi Hirayama
Dec 22, 2012·International Heart Journal·Masanori SakaguchiShigefumi Suehiro
Mar 1, 2013·Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia·Eiki NagaokaNaoto Miyagi
Feb 27, 2014·Asian Cardiovascular & Thoracic Annals·Shinji OgawaHiroshi Baba
Sep 11, 2014·Journal of Clinical Anesthesia·Katsumi SuzukiNaoyuki Matsuda
Aug 12, 2015·World Journal of Critical Care Medicine·Masaki OkajimaTakumi Taniguchi
Jul 5, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Günther KrumplJuri Hodisch
Jul 28, 2016·The Journal of Pharmacology and Experimental Therapeutics·Shahrooz Nasrollahi-ShiraziChristian Nanoff
Aug 28, 2016·European Heart Journal·Paulus KirchhofUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.